Tislelizumab for relapsed/refractory peripheral T-cell lymphomas

 ABSTRACT   06/2020

For more information about this resource, please submit a medical information request.

Tislelizumab (BGB-A317) for relapsed/refractory peripheral T-cell lymphomas: safety and efficacy results from a phase 2 study

Rating

Rate this resource

Nice to see you!

For newest details on our EHA materials in a personal video meeting, please click here!
Service